Pamplona, March 13, 2026 – 3PBIOVIAN, a leading Contract Development and Manufacturing Organization (CDMO), and the National Cancer Institute (Instituto Nacional de Cancerología) in Colombia (INC) has signed a contract to carry out the development of a biosimilar monoclonal antibody (mAb) for an oncology indication, marking the first biosimilar mAb to be developed specifically for expanding access to oncology treatments in Colombia.
The agreement covers the full process development, including cell line development, process and analytical method development, process scale-up, and technology transfer to the client’s facilities in Colombia, where manufacturing will ultimately take place to supply product for patient care.
For 3PBIOVIAN, the contract represents a significant milestone in strengthening its track record in full mammalian development, from cell line creation through industrial-scale process transfer. It also allows 3PBIOVIAN to participate in this highly important initiative to expand patient access to valuable therapeutics against cancer. For its Colombian partner, the project is a strategic step forward for the country’s biopharmaceutical industry, aligned with national efforts to build local biomanufacturing capacity and reduce dependence on imported biologics.
“We are proud to contribute to this project, which truly reflects 3PBIOVIAN’s purpose: to enable global access to high-quality biopharmaceuticals,” said Dámaso Molero, Group CEO. “This collaboration reinforces our experience in mammalian development programs and our commitment to international partnerships that make a real impact on patients’ lives.”
The project represents an innovative initiative for Colombia, driven by the ambition to expand access to affordable biologic medicines. The production of this biosimilar mAb is expected to improve access to oncology treatments for Colombian patients and to strengthen the country’s biotechnological sovereignty.
With this agreement, 3PBIOVIAN consolidates its position as a trusted partner for the development and manufacturing of complex biological products, combining scientific excellence, regulatory expertise, and strong social commitment.